Cargando…

Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma

Despite intensive study, many mysteries remain about the MYCN oncogene's functions. Here we focus on MYCN's role in neuroblastoma, the most common extracranial childhood cancer. MYCN gene amplification occurs in 20% of cases, but other recurrent somatic mutations are rare. This scarcity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Duffy, David J., Krstic, Aleksandar, Halasz, Melinda, Schwarzl, Thomas, Fey, Dirk, Iljin, Kristiina, Mehta, Jai Prakash, Killick, Kate, Whilde, Jenny, Turriziani, Benedetta, Haapa-Paananen, Saija, Fey, Vidal, Fischer, Matthias, Westermann, Frank, Henrich, Kai-Oliver, Bannert, Steffen, Higgins, Desmond G., Kolch, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791225/
https://www.ncbi.nlm.nih.gov/pubmed/26673823
_version_ 1782421048717737984
author Duffy, David J.
Krstic, Aleksandar
Halasz, Melinda
Schwarzl, Thomas
Fey, Dirk
Iljin, Kristiina
Mehta, Jai Prakash
Killick, Kate
Whilde, Jenny
Turriziani, Benedetta
Haapa-Paananen, Saija
Fey, Vidal
Fischer, Matthias
Westermann, Frank
Henrich, Kai-Oliver
Bannert, Steffen
Higgins, Desmond G.
Kolch, Walter
author_facet Duffy, David J.
Krstic, Aleksandar
Halasz, Melinda
Schwarzl, Thomas
Fey, Dirk
Iljin, Kristiina
Mehta, Jai Prakash
Killick, Kate
Whilde, Jenny
Turriziani, Benedetta
Haapa-Paananen, Saija
Fey, Vidal
Fischer, Matthias
Westermann, Frank
Henrich, Kai-Oliver
Bannert, Steffen
Higgins, Desmond G.
Kolch, Walter
author_sort Duffy, David J.
collection PubMed
description Despite intensive study, many mysteries remain about the MYCN oncogene's functions. Here we focus on MYCN's role in neuroblastoma, the most common extracranial childhood cancer. MYCN gene amplification occurs in 20% of cases, but other recurrent somatic mutations are rare. This scarcity of tractable targets has hampered efforts to develop new therapeutic options. We employed a multi-level omics approach to examine MYCN functioning and identify novel therapeutic targets for this largely un-druggable oncogene. We used systems medicine based computational network reconstruction and analysis to integrate a range of omic techniques: sequencing-based transcriptomics, genome-wide chromatin immunoprecipitation, siRNA screening and interaction proteomics, revealing that MYCN controls highly connected networks, with MYCN primarily supressing the activity of network components. MYCN's oncogenic functions are likely independent of its classical heterodimerisation partner, MAX. In particular, MYCN controls its own protein interaction network by transcriptionally regulating its binding partners. Our network-based approach identified vulnerable therapeutically targetable nodes that function as critical regulators or effectors of MYCN in neuroblastoma. These were validated by siRNA knockdown screens, functional studies and patient data. We identified β-estradiol and MAPK/ERK as having functional cross-talk with MYCN and being novel targetable vulnerabilities of MYCN-amplified neuroblastoma. These results reveal surprising differences between the functioning of endogenous, overexpressed and amplified MYCN, and rationalise how different MYCN dosages can orchestrate cell fate decisions and cancerous outcomes. Importantly, this work describes a systems-level approach to systematically uncovering network based vulnerabilities and therapeutic targets for multifactorial diseases by integrating disparate omic data types.
format Online
Article
Text
id pubmed-4791225
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-47912252016-03-28 Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma Duffy, David J. Krstic, Aleksandar Halasz, Melinda Schwarzl, Thomas Fey, Dirk Iljin, Kristiina Mehta, Jai Prakash Killick, Kate Whilde, Jenny Turriziani, Benedetta Haapa-Paananen, Saija Fey, Vidal Fischer, Matthias Westermann, Frank Henrich, Kai-Oliver Bannert, Steffen Higgins, Desmond G. Kolch, Walter Oncotarget Priority Research Paper Despite intensive study, many mysteries remain about the MYCN oncogene's functions. Here we focus on MYCN's role in neuroblastoma, the most common extracranial childhood cancer. MYCN gene amplification occurs in 20% of cases, but other recurrent somatic mutations are rare. This scarcity of tractable targets has hampered efforts to develop new therapeutic options. We employed a multi-level omics approach to examine MYCN functioning and identify novel therapeutic targets for this largely un-druggable oncogene. We used systems medicine based computational network reconstruction and analysis to integrate a range of omic techniques: sequencing-based transcriptomics, genome-wide chromatin immunoprecipitation, siRNA screening and interaction proteomics, revealing that MYCN controls highly connected networks, with MYCN primarily supressing the activity of network components. MYCN's oncogenic functions are likely independent of its classical heterodimerisation partner, MAX. In particular, MYCN controls its own protein interaction network by transcriptionally regulating its binding partners. Our network-based approach identified vulnerable therapeutically targetable nodes that function as critical regulators or effectors of MYCN in neuroblastoma. These were validated by siRNA knockdown screens, functional studies and patient data. We identified β-estradiol and MAPK/ERK as having functional cross-talk with MYCN and being novel targetable vulnerabilities of MYCN-amplified neuroblastoma. These results reveal surprising differences between the functioning of endogenous, overexpressed and amplified MYCN, and rationalise how different MYCN dosages can orchestrate cell fate decisions and cancerous outcomes. Importantly, this work describes a systems-level approach to systematically uncovering network based vulnerabilities and therapeutic targets for multifactorial diseases by integrating disparate omic data types. Impact Journals LLC 2015-12-11 /pmc/articles/PMC4791225/ /pubmed/26673823 Text en Copyright: © 2015 Duffy et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Priority Research Paper
Duffy, David J.
Krstic, Aleksandar
Halasz, Melinda
Schwarzl, Thomas
Fey, Dirk
Iljin, Kristiina
Mehta, Jai Prakash
Killick, Kate
Whilde, Jenny
Turriziani, Benedetta
Haapa-Paananen, Saija
Fey, Vidal
Fischer, Matthias
Westermann, Frank
Henrich, Kai-Oliver
Bannert, Steffen
Higgins, Desmond G.
Kolch, Walter
Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma
title Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma
title_full Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma
title_fullStr Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma
title_full_unstemmed Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma
title_short Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma
title_sort integrative omics reveals mycn as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma
topic Priority Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791225/
https://www.ncbi.nlm.nih.gov/pubmed/26673823
work_keys_str_mv AT duffydavidj integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT krsticaleksandar integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT halaszmelinda integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT schwarzlthomas integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT feydirk integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT iljinkristiina integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT mehtajaiprakash integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT killickkate integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT whildejenny integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT turrizianibenedetta integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT haapapaananensaija integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT feyvidal integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT fischermatthias integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT westermannfrank integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT henrichkaioliver integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT bannertsteffen integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT higginsdesmondg integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma
AT kolchwalter integrativeomicsrevealsmycnasaglobalsuppressorofcellularsignallingandenablesnetworkbasedtherapeutictargetdiscoveryinneuroblastoma